- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02643251
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
August 23, 2017 updated by: BioDelivery Sciences International
A Multicenter, Randomized, Double Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1%, to Clonidine Hydrochloride Gel Comparator in the Management of Painful Diabetic Neuropathy
The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase.
Subjects who qualify to participate will apply study drug to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS) during the Treatment Phase for 12 weeks.
Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Study CLO-291 is a randomized, double-blind, comparator-controlled, parallel-group, multicenter study of 0.1% clonidine topical gel (Clonidine Gel) for the treatment of pain associated with painful diabetic neuropathy.
The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase.
Subjects who satisfy all eligibility criteria will apply Clonidine Gel Comparator to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS).
Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator during the 12 week Treatment Phase.
Study Type
Interventional
Enrollment (Actual)
138
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Glendale, Arizona, United States, 85308
-
Phoenix, Arizona, United States, 85023
-
Phoenix, Arizona, United States, 85018
-
-
California
-
Anaheim, California, United States, 92801
-
Norco, California, United States, 92860
-
Sacramento, California, United States, 95821
-
Santa Monica, California, United States, 90404
-
Tustin, California, United States, 92780
-
-
Florida
-
Fort Myers, Florida, United States, 33912
-
Ocala, Florida, United States, 34471
-
Orlando, Florida, United States, 32801
-
Tampa, Florida, United States, 33634
-
West Palm Beach, Florida, United States, 33401
-
-
Idaho
-
Blackfoot, Idaho, United States, 83321
-
Boise, Idaho, United States, 83642
-
-
Illinois
-
Belleville, Illinois, United States, 62220
-
Blue Island, Illinois, United States, 60406
-
Chicago, Illinois, United States, 60616
-
-
Missouri
-
Hazelwood, Missouri, United States, 63042
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
-
-
Texas
-
Houston, Texas, United States, 77030
-
San Antonio, Texas, United States, 78218
-
San Antonio, Texas, United States, 78228
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is fluent in English and has provided written informed consent.
- Subject is an outpatient ≥18 years of age at the time of the Screening Visit.
- Subject has Type 1 or Type 2 diabetes mellitus with a hemoglobin A1C value < 10% and has been stable on therapy (diet, oral anti-hyperglycemic, and/or insulin) for at least six (6) months prior to the Screening Visit.
- Subject is a male or non-pregnant, non-lactating female. Females must be practicing an acceptable method of birth control or be surgically sterile or postmenopausal (amenorrhea for ≥12 months). A negative pregnancy test at the Screening and Day 1 visits is required for females of child-bearing potential. Double-barrier methods, hormonal contraceptives, and abstinence are acceptable birth control methods for this study.
- Subject has chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for at least six (6) months. Pain should be clearly localized to the area of neuropathy (feet), and subjects should be able to distinguish the target pain from other painful areas and conditions.
- Subject has an average pain score relevant to the target pain in the feet of ≥4 on an 11 point numerical pain rating scale over the previous 24 hours at the Screening Visit.
- Subject meets a pre-specified, minimum numerical pain rating scale score following capsaicin skin challenge.
- Subject must satisfactorily complete Accurate Pain Reporting and Minimizing Placebo Response Training.
- Subject must have moderate to severe pain during the Screening Run-in Phase.
- Subjects must be 75 to 110% compliant with application of study drug during the Screening Run-in Phase
- Subject has been medically stable for at least 30 days prior to the Screening Visit, and in the opinion of the Investigator, is in otherwise good general health based on medical history, physical examination, electrocardiogram, and laboratory evaluation.
Exclusion Criteria:
- Subject has neuropathy secondary to non-diabetic causes in the opinion of the Investigator (e.g., vasculitis, familial neuropathy, alcoholism, pernicious anemia, hepatitis, malignancy, chronic inflammatory demyelinating polyneuropathy [CIDP], human immunodeficiency virus [HIV], medication-induced neuropathy, vitamin B12 deficiency).
- Subject has a significant neurological disorder or condition that might confound assessment of painful diabetic neuropathy (e.g., stroke with distal neurological deficit, mononeuritis multiplex, lumbar radiculopathy).
- Subject has a confounding disorder as determined by the Algorithm for Excluding Disorders that Masquerade as Painful Diabetic Neuropathy.
- Subject has other sustained pain with intensity at or greater than the bilateral neuropathic pain in the feet.
- Subject is using an implanted medical device (e.g., spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for treatment of pain.
- Subject is hypotensive with a resting diastolic blood pressure <60 mm Hg or a systolic blood pressure <90 mm Hg at the Screening or Day 1 Visit.
- The subject has recent history (within the past 3 months) or current symptoms of orthostatic hypotension.
- Subject has a history of foot or toe amputation or an active foot or toe ulcer.
- Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study.
- Subject has a history of substance abuse disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, within the past year, has current evidence of substance abuse disorder, is receiving medical treatment for drug abuse, or has a positive urine drug screen for a non-prescribed substance of abuse.
- Subject is receiving or has received within 30 days prior to the Screening Visit any prohibited medications or is anticipated to receive after the start of the trial any new prescription medication for their painful diabetic neuropathy. Subjects may be enrolled if stable on therapy for painful diabetic neuropathy.
- Subject has symptomatic or severe coronary insufficiency, clinically significant cardiac conduction disturbances, myocardial infarction (within last 12 months), moderate to severe cerebrovascular disease, or severe chronic obstructive pulmonary disease (COPD).
- Subject has estimated creatinine clearance less than 50 mL/min (Cockcroft Gault) at the Screening Visit.
- Subject has serum alanine transaminase (ALT) or aspartate transaminase (AST) >3.0 times the upper limit of normal or total bilirubin concentrations >2.0 times the upper limit of normal at the Screening Visit.
- Subject has received an investigational drug within 30 days prior to the Screening Visit.
- Subject has been treated previously with clonidine topical gel or participated in a clonidine topical gel clinical study, including Study CLO 290.
- Subject is currently taking or has taken clonidine (any formulation) over the past 4 weeks.
- Subject has known hypersensitivity or intolerance to clonidine.
- Subject is receiving or has received ≤7 days prior to the start of the Screening Phase "alternative medicine" products or treatments (e.g., acupuncture, naturopathy, homeopathy, etc.) for management of pain.
- Subject has a history of malignancy within the past 5 years except for successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin and/or localized carcinoma in situ of the cervix.
- Subject is planning to have surgery during the course of the study.
- Subject has significant skin changes on physical examination associated with either pedal edema or venous stasis disease.
- Subject has any dermatologic condition of the lower extremities that could affect study drug absorption
- Subject has current symptoms of depression with a Beck Depression Inventory II (BDI II) score >19 at the Screening Visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clonidine Hydrochloride Topical Gel,0.1%
|
Clonidine Gel is supplied as an aqueous gel formulation for topical use.
Other Names:
|
Placebo Comparator: Clonidine Hydrochloride Gel Comparator
|
Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score
Time Frame: The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])
|
The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable.
The change from baseline can range from -10 to 10.
The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days]) in the Numeric Pain Rating Scale score assessing the "average pain in the past 24 hours in the painful areas of the feet" averaged over Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8).
For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate.
The statistical model also included treatment, site, site by treatment interaction, and strata.
If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.
|
The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores
Time Frame: The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])
|
The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable.
The change from baseline can range from -10 to 10.
The change from Baseline (worse score from Day -14 to Day -8) to End-of-Treatment (worse score during Days 78 to 84 [±3 days]) in the Numeric Pain Rating Scale score assessing the "worse pain in the past 24 hours in the painful areas of the feet" from Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8).
For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate.
The statistical model also included treatment, site, site by treatment interaction, and strata.
If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.
|
The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Aziz Shaibani, MD, Nerve and Muscule Center of Texas
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Actual)
November 1, 2016
Study Completion (Actual)
November 1, 2016
Study Registration Dates
First Submitted
December 29, 2015
First Submitted That Met QC Criteria
December 29, 2015
First Posted (Estimate)
December 31, 2015
Study Record Updates
Last Update Posted (Actual)
September 20, 2017
Last Update Submitted That Met QC Criteria
August 23, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Pain
- Diabetic Neuropathies
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympatholytics
- Clonidine
Other Study ID Numbers
- CLO-291
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathy
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
Nihon Pharmaceutical Co., LtdCompletedMultifocal Motor NeuropathyJapan
-
University of AarhusCompletedMultifocal Motor NeuropathyDenmark
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Yung-Tsan WuCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Sorlandet Hospital HFOslo University Hospital; University Hospital of North Norway; University Hospital...Not yet recruitingSmall Fiber Neuropathy | Sensory Neuropathy
-
Tri-Service General HospitalCompleted
Clinical Trials on Clonidine Hydrochloride Topical Gel, 0.1%
-
Galderma R&DCompletedAcne VulgarisUnited States, Canada
-
BioDelivery Sciences InternationalCompletedDiabetes | Painful Diabetic NeuropathyUnited States
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Galderma R&DCompleted
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Maruho Co., Ltd.Leiden University Medical CenterCompletedCondylomata Acuminata (External)Netherlands
-
Maruho Co., Ltd.CompletedUsual Type Vulval Intraepithelial Neoplasia (uVIN)Netherlands
-
Maruho Co., Ltd.Completed